Best hospitals for Rheumatology: A 2026-2027 evidence review

For readers researching the best hospitals for Rheumatology, the latest U.S. News & World Report specialty ranking places Johns Hopkins Hospital first in the United States for 2026-2027, followed by Cleveland Clinic, Hospital for Special Surgery, Mayo Clinic, and Brigham and Women’s Hospital. The ranking was based on expert opinion from a survey of rheumatologists, rather than a complete clinical-outcomes scorecard. 1

What the latest national ranking shows

The 2026-2027 U.S. News rheumatology ranking identifies Johns Hopkins Hospital as the leading institution, with Cleveland Clinic second and a combined Hospital for Special Surgery-New York-Presbyterian University Hospital of Columbia and Cornell placement third. Mayo Clinic in Rochester ranked fourth, while Brigham and Women’s Hospital ranked fifth. Massachusetts General Hospital also appeared in the published top group. 1

How the ranking should be interpreted

The rheumatology list was based on expert opinion collected through a survey, while other U.S. News specialties incorporate different performance measures. U.S. News contacted 7,612 rheumatologists and reported a 7.4% response rate, so the results indicate professional reputation and perceived capability rather than a direct comparison of every patient outcome, appointment experience, insurance arrangement, or treatment result. 1

Hospital rankings are therefore one reference point rather than a universal answer for every diagnosis. Rheumatology includes common arthritis, inflammatory arthritis, connective-tissue disease, vasculitis, osteoporosis, and multisystem autoimmune disorders. A program’s relevance may depend more on disease-specific expertise, coordinated specialty care, clinical trials, and geographic feasibility than on its overall position. This distinction is especially important when comparing institutions with different clinical missions.

Johns Hopkins and Cleveland Clinic

Johns Hopkins combines specialty care with substantial academic and research infrastructure. Its Arthritis Center is directed by Clifton Bingham III, whose stated clinical interests include rheumatoid arthritis and other inflammatory arthritis; the center includes eight rheumatologists, two nurses, and a research staff, and reports more than 4,500 patient visits each year. 8 Ami Shah directs the rheumatology division and co-directs the Scleroderma Center, with expertise involving scleroderma, Raynaud’s phenomenon, and related complications. 9

Cleveland Clinic ranked second nationally for rheumatology in the 2026-2027 U.S. News results and was nationally ranked in 13 of 14 specialties overall. Its institutional description emphasizes acceptance of challenging cases, while its rheumatology position places it among the leading programs for systemic autoimmune disease and complex care. 4 These profiles suggest different but overlapping strengths: Johns Hopkins has detailed arthritis, scleroderma, and outcomes-research leadership, while Cleveland Clinic offers a broad tertiary-care environment.

Hospital for Special Surgery and Mayo Clinic

Hospital for Special Surgery ranked third nationally for rheumatology in the cited 2026-2027 listing. HSS also reported a record 17th consecutive No. 1 ranking in orthopedics, making its institutional identity particularly focused on musculoskeletal medicine. U.S. News evaluated nearly 4,500 hospitals across 14 specialties and considered measures such as patient outcomes, nursing care, patient-reported experience, and technology for its broader specialty methodology. 2

Mayo Clinic in Rochester ranked fourth in the latest supplied rheumatology list, despite broader background material describing it as consistently highly ranked. That difference illustrates why ranking year and specialty methodology matter. A hospital’s national visibility does not establish that it is the most suitable setting for every patient, and the available data does not provide a diagnosis-by-diagnosis comparison of Mayo Clinic against the other institutions listed here.

Boston, California, and Pennsylvania programs

Brigham and Women’s Hospital ranked fifth in the 2026-2027 national rheumatology list, while Massachusetts General Hospital was also included among the published leading facilities. Background research identifies Brigham and Women’s as an institution associated with clinical research in rheumatoid arthritis and lupus. The supplied data does not provide trial counts, enrollment criteria, or comparative outcome measures, so those research descriptions should be treated as program characteristics rather than proof of superior results.

UCSF Health describes board-certified rheumatologists working with nephrology, pulmonology, dermatology, cardiology, ophthalmology, and neurology for complex inflammatory and autoimmune disease. It also identifies expertise in less common conditions such as scleroderma and dermatomyositis, dedicated support staff, and rheumatology research. 3 Penn Medicine similarly describes care for common and rare rheumatic diseases, specialized centers for vasculitis, Sjögren’s disease, relapsing polychondritis, and antiphospholipid syndrome, plus clinical trials and second opinions. 5

Multidisciplinary and international alternatives

Montefiore Einstein Advanced Care describes a rheumatology model using musculoskeletal ultrasound, focused subspecialty clinics, multidisciplinary collaboration, and clinical trials for autoimmune and inflammatory conditions. Its listed collaborators include cardiology, dermatology, nephrology, neurology, pulmonology, oncology, ophthalmology, orthopedics, and rehabilitation. 6 Such coordination may be particularly relevant when a rheumatic disease affects several organs, although the supplied information does not compare its outcomes with nationally ranked hospitals.

Outside the United States, Sheba Medical Center in Israel describes rheumatoid arthritis treatment using conventional disease-modifying drugs, biologic agents, targeted synthetic therapies, advanced imaging, and molecular diagnostics. It also reports a research program involving CD19-targeted CAR T-cell therapy for a small group of refractory patients. 7 Acibadem’s rheumatology information highlights treat-to-target care, biologic pathways, ultrasound, vasculitis, Behçet disease, and familial Mediterranean fever. 10 International care introduces additional considerations involving travel, language, continuity, and local regulation.

Factors to assess before choosing a hospital

The most useful comparison begins with the specific disease and the level of complexity involved. Patients and referring clinicians can assess whether the hospital has relevant subspecialists, coordinated care for affected organs, diagnostic tools such as musculoskeletal ultrasound, clinical-trial pathways, and experience with rare or treatment-resistant disease. The available sources also show that programs differ in emphasis, ranging from arthritis and scleroderma research to orthopedic medicine, systemic autoimmune disease, and international treatment programs.

• Confirm that the program treats the relevant diagnosis and age group.
• Review whether referrals, prior records, imaging, or laboratory documentation are required.
• Ask how rheumatology coordinates with nephrology, pulmonology, dermatology, neurology, cardiology, or rehabilitation when needed.
• Evaluate travel distance, follow-up logistics, language support, and continuity with local clinicians.
• For clinical trials, review eligibility, study design, potential risks, oversight, and follow-up obligations.

Important friction points include limited ranking response rates, differences in hospital missions, insurance-network restrictions, referral procedures, appointment capacity, and the practical burden of repeated visits. Clinical-trial participation may involve strict eligibility rules and additional monitoring, while advanced therapies require specialist assessment and ongoing follow-up. These considerations are not captured fully by a national rank and should be weighed alongside the diagnosis, treatment history, and advice of a qualified clinician.

Overall interpretation

For the 2026-2027 U.S. rheumatology ranking supplied here, Johns Hopkins Hospital is the highest-ranked institution, followed by Cleveland Clinic, HSS and affiliated New York hospitals, Mayo Clinic Rochester, and Brigham and Women’s Hospital. Other programs, including UCSF, Penn Medicine, Montefiore Einstein, Sheba, and Acibadem, describe specialized services or research capabilities that may be relevant for particular conditions. 1

No single ranking can determine the appropriate hospital for every rheumatic disease. The strongest evaluation combines current specialty recognition with disease-specific expertise, multidisciplinary capacity, research or trial relevance, treatment continuity, eligibility requirements, and realistic travel and coverage considerations. The supplied evidence supports using rankings as a starting framework, not as a substitute for individualized medical assessment.

Sources

1. Healio, “U.S. News names Johns Hopkins best rheumatology hospital for 2026-2027”
2. Hospital for Special Surgery, “HSS Extends Its National Leadership with 17th Consecutive No. 1 Ranking in Orthopedics and No. 3 Ranking in Rheumatology”
3. UCSF Health, “Rheumatology”
4. Cleveland Clinic, “Cleveland Clinic One of the Nation’s Best Hospitals”
5. Penn Medicine, “Rheumatology”
6. Montefiore Einstein Advanced Care, “Rheumatology”
7. Sheba Medical Center, “Rheumatoid Arthritis Treatment”
8. Johns Hopkins Medicine, profile of Clifton Bingham III, MD
9. Johns Hopkins Medicine, profile of Ami Shah, MD
10. Acibadem International, “Rheumatology Department”